Singapore Health Sciences Authority: Four reports of 'non-serious adverse events' in over 2,000 doses of Nuvaxovid Covid-19 vaccine administered

1 month ago 62

The Nuvaxovid Covid-19 vaccine uses a long-established protein-based technology that is an alternative to the messenger ribonucleic acid (mRNA) vaccines by Pfizer-BioNTech and Moderna. ― BELGA via Reuters

Follow us on Instagram, subscribe to our Telegram channel and browser alerts for the latest news you need to know.

Tuesday, 28 Jun 2022 9:36 AM MYT

SINGAPORE, June 28 — As of May 31, there have been four reports of "non-serious adverse events" in the two weeks following the roll-out of the Nuvaxovid Covid-19 vaccine in Singapore, the Health Sciences Authority (HSA) said yesterday (June 27).

These events included dizziness, rash, vasculitis (inflammation of blood vessels) and chest pain.

“These are largely consistent with what was reported in the clinical studies and are known adverse effects associated with vaccines,” HSA said in its 12th vaccine safety report, which covers the period from December 30, 2020, to May 31 this year.

A total of 2,792 doses of the Nuvaxovid Covid-19 vaccine have been administered as of May 31 since the rollout of the vaccine on May 18, 2022.

The Nuvaxovid Covid-19 vaccine uses a long-established protein-based technology that is an alternative to the mess...

Read Entire Article